Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synergen

Executive Summary

Reacquires rights to interleukin-1 receptor antagonist (IL-1ra) from Hoffmann-La Roche. Product is in preclinicals for autoimmune and inflammatory diseases, including rheumatoid arthritis. Worldwide rights to IL-1ra revert to Synergen. Other terms of the agreement were not disclosed. The Boulder, Colorado-based biotech firm and Roche entered into a collaborative effort on the product in May 1989. Synergen, which has approximately $50 mil. in cash on hand, said termination of the agreement would not affect the development of IL-1ra or its other projects, even though Roche's payments accounted for 64% of contract R&D revenues in 1989 and 61% during the first quarter of 1990. The company still expects to being human clinicals on IL-1ra "later this year." Roche's decision followed a reprioritization of its pipeline, according to Synergen.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel